Risk factors for metabolic dysfunction-associated fatty liver disease in the Hispanic-Mexican population
e202306053
Keywords:
Metabolic dysfunction-associated fatty liver disease, Risk factors, Mexican populationAbstract
BACKGROUND // Metabolic dysfunction-associated fatty liver disease (MAFLD) is a poor attended disease, which has gained attention due the elevated number of cases in countries as Mexico, where the incidence is the number 4th globally. MAFLD develops in obese or overweighted individuals and is characterized by triglycerides accumulation in the liver, this condition can develop to hepatocellular carcinoma. It has been observed that MAFLD depends on the genetics and lifestyle. Due to the high prevalence of this disease among Hispanic population, we focused on this study in the characteristics and prevalence of MAFLD in Mexican patients.
METHODS // In this study were included 572 overweighted and obese patients, who underwent a screening analysis using the fatty liver index (IHG), clinical parameters were analysed, demographic and comorbidities. Frequency of variables were obtained, and the data were analysed by Chi-square test or Fisher test, odd ratio (OR) and binary logistic regression.
RESULTS // A MALFD prevalence of 37% were obtained, where the history of familiar obesity, paracetamol usage, carbohydrate and fat intake are shown to be risk factors. It was found that high blood pressure, central obesity and hypertriglyceridemia were also associated to the MAFLD development. On the other hand, physical exercise was a protector factor.
CONCLUSIONS // Our results show the necessity to study the MAFLD causalities in Mexican patients, focused on the paracetamol intake.
Downloads
References
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844-1850.
Palmer ND, Musani SK, Yerges-Armstrong LM, Feitosa MF, Bielak LF, Hernaez R et al. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent. Hepatology. 2013;58(3):966-975.
Day CP. The potential role of genes in nonalcoholic fatty liver disease. Clinics in liver disease. 2004;8(3):673-91, xi.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
Kallwitz ER, Daviglus ML, Allison MA, Emory KT, Zhao L, Kuniholm MH et al. Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage. Clin Gastroenterol Hepatol. 2015;13(3):569-576.
Schneider AL, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity (Silver Spring). 2014;22(1):292-299.
Lazo M, Bilal U, Perez-Escamilla R. Epidemiology of NAFLD and Type 2 Diabetes: Health Disparities Among Persons of Hispanic Origin. Curr Diab Rep. 2015;15(12):116.
Kalia HS, Gaglio PJ. The Prevalence and Pathobiology of Nonalcoholic Fatty Liver Disease in Patients of Different Races or Ethnicities. Clin Liver Dis. 2016;20(2):215-224.
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124-131.
Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012;55(3):769-780.
Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20(2):205-214.
Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology. 2009;49(3):791-801.
Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. Journal of hepatology. 2014;61(1):75-81.
Kallwitz ER, Kumar M, Aggarwal R, Berger R, Layden-Almer J, Gupta N et al. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Digestive diseases and sciences. 2008;53(5):1358-1363.
Wainwright P, Byrne CD. Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. International journal of molecular sciences. 2016;17(3):367.
Hernaez R, McLean J, Lazo M, Brancati FL, Hirschhorn JN, Borecki IB et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2013;11(9):1183-1190 e2.
Lizardi-Cervera J, Laparra DI, Chavez-Tapia NC, Ostos ME, Esquivel MU. [Prevalence of NAFLD and metabolic syndrome in asymtomatics subjects]. Rev Gastroenterol Mex. 2006;71(4):453-459.
Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther. 2017;46(2):85-95.
Naderian M, Kolahdoozan S, Sharifi AS, Garmaroudi G, Yaseri M, Poustchi H et al. Assessment of Lean Patients with Non-alcoholic Fatty Liver Disease in a Middle Income Country; Prevalence and Its Association with Metabolic Disorders: A Cross-sectional Study. Arch Iran Med. 2017;20(4):211-217.
Feng RN, Du SS, Wang C, Li YC, Liu LY, Guo FC et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20(47):17932-17940.
Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004;164(19):2169-2175.
Gonzalez Huezo MS, Sanchez Avila JF, Asociacion Mexicana de H, Asociacion Mexicana de G, Sociedad Mexicana de Radiologia e I, Sociedad Mexicana de O et al. Mexican consensus on the diagnosis and management of hepatocellular carcinoma. Rev Gastroenterol Mex. 2014;79(4):250-262.
Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524-30 e1; quiz e60.
Zelber-Sagi S, Webb M, Assy N, Blendis L, Yeshua H, Leshno M et al. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol. 2013;19(1):57-64.
NORMA Oficial Mexicana NOM-015-SSA2-2010, para la prevención, tratamiento y control de la diabetes mellitus. (2010).
Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
Munro HN. Nutrition and the elderly: a general overview. J Am Coll Nutr. 1984;3(4):341-350.
Roesch-Dietlen F, Dorantes-Cuéllar A, Carrillo-Toledo MG, Martínez-Sibaja C, Rojas-Carrera S, Bonilla-Rojas QC et al. [Frequency of NAFLD in a group of patients with metabolic syndrome in Veracruz, Mexico]. Rev Gastroenterol Mex. 2006;71(4):446-452.
Ortega AN, Rodriguez HP, Vargas Bustamante A. Policy dilemmas in Latino health care and implementation of the Affordable Care Act. Annu Rev Public Health. 2015;36:525-544.
Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014;6(5):274-283.
Cheng H-Y, Wang H-Y, Chang W-H, Lin S-C, Chu C-H, Wang T-E et al. Nonalcoholic Fatty Liver Disease: Prevalence, Influence on Age and Sex, and Relationship with Metabolic Syndrome and Insulin Resistance. International Journal of Gerontology. 2013;7(4):194-198.
Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol. 2002;17(10):1098-1105.
Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care. 2012;35(4):873-878.
Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010;105(7):1567-1573.
Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014;29(11):1926-1931.
Kuzminova N, Gribenyuk O, Osovska N, Knyazkova I. Arterial hypertension, obesity and non-alcoholic fatty liver disease: is there any connection? Arterial Hypertens. 2016;20(4):216-227.
Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45(10):1929-1934.
Ramos-Lopez O, Martinez-Lopez E, Roman S, Fierro NA, Panduro A. Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico. World J Gastroenterol. 2015;21(41):11552-11566.
Wei H, Qu H, Wang H, Deng H. Associations between sitting time and non-alcoholic fatty liver diseases in Chinese male workers: a cross-sectional study. BMJ Open. 2016;6(9):e011939.
Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57(1):157-166.
González-Salazar MC, Medina-Urrutia AX, Juárez-Rojas JG, Cardoso-Saldaña GC, Posadas-Sánchez R, Martínez-Alvarado R et al. [Dietary patterns and physical activity in the mexican population: association with fatty liver]. Gac Med Mex. 2014;150 Suppl 1:39-47.
Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2006;21(1 Pt 1):191-198.
Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol. 2011;17(29):3377-3389.
Guzmán NA, Molina DR, Núñez BF, Soto-Sosa JC, Abarca JE. Bioequivalence and Pharmacokinetic Evaluation Study of Acetaminophen vs. Acetaminophen Plus Caffeine Tablets in Healthy Mexican Volunteers. Drugs R D. 2016;16(4):339-345.
Khedun SM, Maharaj B, Leary WP, Naicker T. The effect of therapeutic doses of paracetamol on liver function in the rat perfused liver. J Pharm Pharmacol. 1993;45(6):566-569.
Kucera O, Al-Dury S, Lotkova H, Rousar T, Rychtrmoc D, Cervinkova Z. Steatotic rat hepatocytes in primary culture are more susceptible to the acute toxic effect of acetaminophen. Physiol Res. 2012;61 Suppl 2:S93-101.
Michaut A, Moreau C, Robin MA, Fromenty B. Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int. 2014;34(7):e171-179.
Michaut A, Le Guillou D, Moreau C, Bucher S, McGill MR, Martinais S et al. A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen. Toxicol Appl Pharmacol. 2016;292:40-55.
Massart J, Begriche K, Moreau C, Fromenty B. Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res. 2017;3(Suppl 1):212-232.
Published
How to Cite
License
Copyright (c) 2023 Jaime Morales-Romero, María Cristina Ortíz-León, Héctor Hernández-Gutiérrez, Roberto A. Bahena-Cerón, Aidé Miranda-Reza, José A. Marín-Carmona, Edit Rodríguez-Romero, Silvia I. Mora, Jonathan García-Román, Julio I. Peréz-Carreón, Eduardo Rivadeneyra-Domínguez, Gabriel Riande-Juárez, Rebeca García-Román
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
